logo-loader
viewMedlab Clinical Ltd

Medlab Clinical has in place 'the fundamentals to a very successful future'

Medlab Clinical Ltd (ASX:MDC) CEO & managing director Dr. Sean Hall speaks with Proactive Investors about the biotech's various research and development programs, focused on delivering therapies for a range of chronic conditions.

"Oncology, specifically pain which is our cannabis area, is a main focal point, it's probably one of our most accelerated areas. Second to that, one of our more recent announcements is in the area of depression where we're looking at increasing efficacy in standard depression medications. Outside that, we have advanced areas of influence in diabetes, chronic kidney disease, ageing... From that we get a pharmaceutical division [that] makes actual drugs that go before registration and we commercialise; [and also] we have a Nutraceutical division that is in-market now," explains Hall.

Trials of Medlab’s NRGBiotic™ product for the treatment of depression are entering Phase II, with Hall describing the research as "a couple of years ahead of its time curve."

Meanwhile, Medlab's cannabis-based research arms are progressing well, with the most-advanced NanaBis™ medication in human trials and licensed under the Therapeutic Goods Administration's (TGA) Special Access Scheme.

Quick facts: Medlab Clinical Ltd

Price: 0.15 AUD

ASX:MDC
Market: ASX
Market Cap: $41.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

2 min read